Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.
Development of new anticancer and anti-inflammatory drugs for personalized medicine
Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.
10, rue de l'Espinay
Canada G1L 3L5
- Carpentier, AntoineDoctoral studentCHUL+1 418-525-4444, extension firstname.lastname@example.org
2705 Boulevard Laurier
Canada G1V 4G2
- Patenaude, AlexandreEmployeeCHUL+1 418-525-4444, extension email@example.com
2705, boulevard Laurier
Canada G1V 4G2
- Sahli, AhmedMaster studentHôpital Saint-François d'Assise+1 418-525-4444, extension firstname.lastname@example.org
10 Rue de l'Espinay
Canada G1L 3L5
Branched alkyl of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as unique cytochrome P450 1A1-activated antimitotic prodrugs: Biological evaluation and mechanism of bioactivationJournal Article
Eur J Med Chem, 229 , 2022.
TBC1D9: An Important Modulator of Tumorigenesis in Breast CancerJournal Article
Cancers (Basel), 13 (14), 2021.
Synthesis and evaluation of substituted phenyl cycloalkylureas and bioisosteres as IL-6 expression inhibitorsJournal Article
Med Chem Res, 20 (8), 2020.
Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugsJournal Article
J Pharm Pharmacol, 72 (2), 2020.
Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activityJournal Article
Eur J Med Chem, 179 , 2019.
Transdermal diffusion, spatial distribution and physical state of a potential anticancer drug in mouse skin as studied by diffusion and spectroscopic techniquesJournal Article
Biomed Spectrosc Imaging, 7 (1-2), 2018.
Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activityJournal Article
Bioorg Med Chem Lett, 27 (2), 2017.
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer CellsJournal Article
J Med Chem, 60 (12), 2017.
Size-Controlled Functionalized Mesoporous Silica Nanoparticles for Tunable Drug Release and Enhanced Anti-Tumoral ActivityJournal Article
Chem Mater, 28 (12), 2016.
Synthesis of novel C-symmetric testosterone dimers and evaluation of antiproliferative activity on androgen-dependent and -independent prostate cancer cell linesJournal Article
Steroids, 115 , 2016.
- Accélérer et rendre plus accessibles les tests précliniques en chimiothérapie et la radiothérapie du cancer, en utilisant le modèle de l'oeuf et des stratégies d'impression 3D, from 2020-04-01 to 2023-03-31
- L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
Recently finished projects
- Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, from 2018-04-01 to 2021-03-31